Provide the generic name (INN), dosage form, active strength, packaging specifications, target market pharmacopoeia (such as USP or EP), order volume, and required registration dossiers to ensure accurate pricing.
Category market report
Other Drugs
Total suppliers
7,541+
Total Chinese suppliers export
$16.6B+
Recommended
High-quality suppliers related to Other Drugs.
Suppliers
Find more suppliers who may be worth contacting.
Top suppliers
Suppliers in this category.
- Transactions
1,880
2018-012022-032026-07Transaction trend for Astrazeneca Pharmaceutical Co., Ltd.
- 2018-01: 4
- 2018-02: 2
- 2018-03: 3
- 2018-04: 4
- 2018-05: 3
- 2018-06: 10
- 2018-07: 5
- 2018-09: 10
- 2018-10: 2
- 2018-11: 1
- 2018-12: 1
- 2019-01: 32
- 2019-02: 19
- 2019-03: 17
- 2019-04: 13
- 2019-05: 19
- 2019-06: 16
- 2019-07: 9
- 2019-08: 5
- 2019-09: 4
- 2019-10: 7
- 2019-11: 13
- 2019-12: 15
- 2020-01: 24
- 2020-02: 1
- 2020-03: 18
- 2020-04: 30
- 2020-05: 27
- 2020-06: 14
- 2020-07: 13
- 2020-08: 38
- 2020-09: 4
- 2020-10: 21
- 2020-11: 28
- 2020-12: 16
- 2021-01: 9
- 2021-02: 42
- 2021-03: 23
- 2021-04: 20
- 2021-05: 44
- 2021-06: 23
- 2021-07: 19
- 2021-08: 33
- 2021-09: 15
- 2021-10: 46
- 2021-11: 27
- 2021-12: 22
- 2022-01: 43
- 2022-02: 9
- 2022-03: 22
- 2022-04: 30
- 2022-05: 24
- 2022-06: 26
- 2022-07: 19
- 2022-08: 18
- 2022-09: 19
- 2022-10: 34
- 2022-11: 12
- 2022-12: 37
- 2023-01: 13
- 2023-02: 19
- 2023-03: 51
- 2023-04: 22
- 2023-05: 12
- 2023-06: 26
- 2023-07: 25
- 2023-08: 18
- 2023-09: 45
- 2023-10: 10
- 2023-11: 32
- 2023-12: 15
- 2024-02: 28
- 2024-03: 12
- 2024-05: 31
- 2024-06: 18
- 2024-07: 16
- 2024-08: 6
- 2024-09: 15
- 2024-10: 16
- 2024-11: 32
- 2024-12: 41
- 2025-01: 41
- 2025-02: 38
- 2025-03: 39
- 2025-04: 13
- 2025-05: 10
- 2025-06: 11
- 2025-07: 37
- 2025-08: 31
- 2025-09: 24
- 2025-10: 21
- 2025-11: 35
- 2025-12: 32
- 2026-01: 48
- 2026-02: 21
- 2026-03: 35
- 2026-04: 63
- 2026-05: 60
- 2026-06: 40
- 2026-07: 37
- Amount
4,100,559.05
2018-012022-032026-07Amount trend for Astrazeneca Pharmaceutical Co., Ltd.
- 2018-01: 19.5M
- 2018-02: 23.3K
- 2018-03: 613.5K
- 2018-04: 401K
- 2018-05: 53.6K
- 2018-06: 195.8K
- 2018-07: 174.2K
- 2018-09: 1.4M
- 2018-10: 143.4K
- 2018-11: 27.6K
- 2018-12: 23K
- 2019-01: 40.7B
- 2019-02: 2.8M
- 2019-03: 2.4M
- 2019-04: 1.7M
- 2019-05: 2.6M
- 2019-06: 3.1M
- 2019-07: 1.8M
- 2019-08: 840.4K
- 2019-09: 772.1K
- 2019-10: 2.5M
- 2019-11: 2M
- 2019-12: 1.8M
- 2020-01: 7M
- 2020-02: 9,942.19
- 2020-03: 3.1M
- 2020-04: 4.1M
- 2020-05: 4.5M
- 2020-06: 5.9M
- 2020-07: 2.1M
- 2020-08: 7.6M
- 2020-09: 281.4K
- 2020-10: 1.8M
- 2020-11: 2.3M
- 2020-12: 2.1M
- 2021-01: 927.7K
- 2021-02: 5.9M
- 2021-03: 3M
- 2021-04: 2.8M
- 2021-05: 6.3M
- 2021-06: 4.1M
- 2021-07: 2.5M
- 2021-08: 4M
- 2021-09: 3.4M
- 2021-10: 7M
- 2021-11: 3.9M
- 2021-12: 4M
- 2022-01: 8.5M
- 2022-02: 2.3M
- 2022-03: 2.2M
- 2022-04: 5.2M
- 2022-05: 2.8M
- 2022-06: 4.1M
- 2022-07: 3.3M
- 2022-08: 2.1M
- 2022-09: 2.8M
- 2022-10: 5.3M
- 2022-11: 2M
- 2022-12: 5.9M
- 2023-01: 1.2M
- 2023-02: 3.3M
- 2023-03: 6.5M
- 2023-04: 3.4M
- 2023-05: 3.1M
- 2023-06: 3.4M
- 2023-07: 2.5M
- 2023-08: 2.8M
- 2023-09: 6.7M
- 2023-10: 1.9M
- 2023-11: 5.4M
- 2023-12: 3.1M
- 2024-02: 8.1M
- 2024-03: 3.1M
- 2024-05: 5.5M
- 2024-06: 3.3M
- 2024-07: 3M
- 2024-08: 1.3M
- 2024-09: 2.5M
- 2024-10: 2.2M
- 2024-11: 2M
- 2024-12: 2M
- 2025-01: 4.8M
- 2025-02: 1.1M
- 2025-03: 2.6M
- 2025-04: 2.9M
- 2025-05: 2.5M
- 2025-06: 1.9M
- 2025-07: 3.2M
- 2025-08: 1.4M
- 2025-09: 3M
- 2025-10: 798.7K
- 2025-11: 2.3M
- 2025-12: 3.3M
- 2026-01: 2.1M
- 2026-02: 2M
- 2026-03: 979.2K
- 2026-04: 3.2M
- 2026-05: 1.9M
- 2026-06: 1.5M
- 2026-07: 410.4K
- Main export countries
- India (0.6%)
- Namibia (0%)
- Sri Lanka (0%)
- Mexico (99.3%)
- Transactions
47
2019-012020-102021-09Transaction trend for Puyang Hotway Pharmacy Co., Ltd.
- 2019-01: 32
- 2019-11: 2
- 2020-04: 2
- 2020-05: 1
- 2020-06: 1
- 2020-10: 1
- 2021-03: 2
- 2021-04: 1
- 2021-05: 1
- 2021-07: 1
- 2021-08: 1
- 2021-09: 2
- Amount
559,462.81
2019-012020-102021-09Amount trend for Puyang Hotway Pharmacy Co., Ltd.
- 2019-01: 5.6B
- 2019-11: 24.9K
- 2020-04: 22.1K
- 2020-05: 11.8K
- 2020-06: 12.3K
- 2020-10: 11.9K
- 2021-03: 24.6K
- 2021-04: 12.5K
- 2021-05: 12.7K
- 2021-07: 12.5K
- 2021-08: 12.5K
- 2021-09: 25.3K
- Main export countries
- Indonesia (100%)
- Transactions
2,144
2018-012022-072026-09Transaction trend for Humanwell Puracap Pharmaceutical Co.
- 2018-01: 9
- 2018-02: 12
- 2018-03: 11
- 2018-04: 8
- 2018-05: 11
- 2018-06: 19
- 2018-07: 14
- 2018-08: 21
- 2018-09: 20
- 2018-10: 15
- 2018-11: 15
- 2018-12: 10
- 2019-01: 21
- 2019-02: 4
- 2019-03: 10
- 2019-04: 12
- 2019-05: 19
- 2019-06: 9
- 2019-07: 7
- 2019-08: 17
- 2019-09: 14
- 2019-11: 23
- 2019-12: 16
- 2020-01: 14
- 2020-02: 18
- 2020-03: 6
- 2020-05: 6
- 2020-06: 22
- 2020-08: 18
- 2020-10: 21
- 2020-11: 21
- 2020-12: 8
- 2021-01: 10
- 2021-02: 9
- 2021-03: 19
- 2021-04: 11
- 2021-05: 16
- 2021-06: 9
- 2021-07: 17
- 2021-08: 12
- 2021-09: 8
- 2021-10: 18
- 2021-11: 20
- 2021-12: 28
- 2022-01: 12
- 2022-02: 18
- 2022-03: 19
- 2022-05: 17
- 2022-06: 19
- 2022-07: 25
- 2022-08: 15
- 2022-09: 41
- 2022-10: 25
- 2022-11: 28
- 2022-12: 38
- 2023-01: 30
- 2023-02: 11
- 2023-03: 43
- 2023-04: 42
- 2023-05: 29
- 2023-06: 18
- 2023-07: 25
- 2023-08: 19
- 2023-09: 15
- 2023-10: 27
- 2023-11: 24
- 2023-12: 20
- 2024-01: 44
- 2024-02: 34
- 2024-03: 21
- 2024-04: 37
- 2024-05: 32
- 2024-06: 19
- 2024-07: 16
- 2024-08: 14
- 2024-09: 21
- 2024-10: 35
- 2024-11: 44
- 2024-12: 56
- 2025-01: 39
- 2025-02: 43
- 2025-03: 41
- 2025-04: 28
- 2025-05: 31
- 2025-06: 21
- 2025-07: 32
- 2025-08: 13
- 2025-09: 16
- 2025-10: 20
- 2025-11: 15
- 2025-12: 16
- 2026-01: 24
- 2026-02: 22
- 2026-03: 30
- 2026-04: 23
- 2026-05: 37
- 2026-06: 46
- 2026-07: 14
- 2026-08: 14
- 2026-09: 5
- Amount
83,182.16
2018-012022-072026-09Amount trend for Humanwell Puracap Pharmaceutical Co.
- 2018-01: 3.5M
- 2018-02: 4.8M
- 2018-03: 4.8M
- 2018-04: 3.3M
- 2018-05: 2M
- 2018-06: 5.1M
- 2018-07: 2.9M
- 2018-08: 5.5M
- 2018-09: 5.5M
- 2018-10: 4.2M
- 2018-11: 7.5M
- 2018-12: 2.4M
- 2019-01: 6.4M
- 2019-02: 1.4M
- 2019-03: 5.2M
- 2019-04: 4.2M
- 2019-05: 5.2M
- 2019-06: 3M
- 2019-07: 2.3M
- 2019-08: 5M
- 2019-09: 4.6M
- 2019-11: 6.8M
- 2019-12: 3.5M
- 2020-01: 3.7M
- 2020-02: 6.2M
- 2020-03: 2.5M
- 2020-05: 1.9M
- 2020-06: 12.1M
- 2020-08: 5.9M
- 2020-10: 11M
- 2020-11: 13M
- 2020-12: 4.8M
- 2021-01: 5.9M
- 2021-02: 3.7M
- 2021-03: 11.4M
- 2021-04: 5.1M
- 2021-05: 6.3M
- 2021-06: 5.5M
- 2021-07: 9.4M
- 2021-08: 8.4M
- 2021-09: 3.1M
- 2021-10: 9.9M
- 2021-11: 11.6M
- 2021-12: 13.5M
- 2022-01: 7.1M
- 2022-02: 12.3M
- 2022-03: 9.4M
- 2022-05: 8.1M
- 2022-06: 14.3M
- 2022-07: 16.1M
- 2022-08: 6.7M
- 2022-09: 15.5M
- 2022-10: 10.7M
- 2022-11: 12.3M
- 2022-12: 36.8M
- 2023-01: 13.5M
- 2023-02: 5.4M
- 2023-03: 17.7M
- 2023-04: 21M
- 2023-05: 11M
- 2023-06: 11.2M
- 2023-07: 9.1M
- 2023-08: 8.5M
- 2023-09: 6.3M
- 2023-10: 9.8M
- 2023-11: 9.2M
- 2023-12: 7.8M
- 2024-01: 16.7M
- 2024-02: 13.6M
- 2024-03: 6.9M
- 2024-04: 11M
- 2024-05: 10.4M
- 2024-06: 7.2M
- 2024-07: 9.3M
- 2024-08: 6.6M
- 2024-09: 5.2M
- 2024-10: 11.5M
- 2024-11: 10.1M
- 2024-12: 12.5M
- 2025-01: 10.9M
- 2025-02: 9.8M
- 2025-03: 7.5M
- 2025-04: 4.7M
- 2025-05: 7.4M
- 2025-06: 4.7M
- 2025-07: 12.4M
- 2025-08: 3.5M
- 2025-09: 5.5M
- 2025-10: 5.4M
- 2025-11: 3.7M
- 2025-12: 4.2M
- 2026-01: 6.1M
- 2026-02: 6.3M
- 2026-03: 8.5M
- 2026-04: 6.3M
- 2026-05: 16.2M
- 2026-06: 13.9M
- 2026-07: 3.7M
- 2026-08: 4.2M
- 2026-09: 1.5M
- Main export countries
- United States (99.1%)
- India (0%)
- Not available (0.9%)
Intelligence
China export momentum, destination markets, and regional demand.
China export trend
China export trend
- Date 2018-07: Value 3.8B USD
- Date 2018-08: Value 3.6B USD
- Date 2018-09: Value 3.3B USD
- Date 2018-10: Value 3.5B USD
- Date 2018-11: Value 4.1B USD
- Date 2018-12: Value 4B USD
- Date 2019-01: Value 3.9B USD
- Date 2019-02: Value 2.7B USD
- Date 2019-03: Value 4B USD
- Date 2019-04: Value 4.3B USD
- Date 2019-05: Value 4.6B USD
- Date 2019-06: Value 3.8B USD
- Date 2019-07: Value 4.4B USD
- Date 2019-08: Value 4.5B USD
- Date 2019-09: Value 4.2B USD
- Date 2019-10: Value 4.6B USD
- Date 2019-11: Value 5B USD
- Date 2019-12: Value 5B USD
- Date 2020-01: Value 0 USD
- Date 2020-02: Value 7.2B USD
- Date 2020-03: Value 5.6B USD
- Date 2020-04: Value 5B USD
- Date 2020-05: Value 4.1B USD
- Date 2020-06: Value 0 USD
- Date 2020-07: Value 0 USD
- Date 2020-08: Value 0 USD
- Date 2020-09: Value 4.8B USD
- Date 2020-10: Value 3.5B USD
- Date 2020-11: Value 4.5B USD
- Date 2020-12: Value 3.9B USD
- Date 2021-01: Value 263M USD
- Date 2021-02: Value 254M USD
- Date 2021-03: Value 338M USD
- Date 2021-04: Value 312M USD
- Date 2021-05: Value 309M USD
- Date 2021-06: Value 301M USD
- Date 2021-07: Value 336M USD
- Date 2021-08: Value 335M USD
- Date 2021-09: Value 445M USD
- Date 2021-10: Value 371M USD
- Date 2021-11: Value 376M USD
- Date 2021-12: Value 356M USD
- Date 2022-01: Value 484M USD
- Date 2022-02: Value 323M USD
- Date 2022-03: Value 422M USD
- Date 2022-04: Value 358M USD
- Date 2022-05: Value 423M USD
- Date 2022-06: Value 328M USD
- Date 2022-07: Value 341M USD
- Date 2022-08: Value 390M USD
- Date 2022-09: Value 378M USD
- Date 2022-10: Value 335M USD
- Date 2022-11: Value 410M USD
- Date 2022-12: Value 336M USD
- Date 2023-01: Value 297M USD
- Date 2023-02: Value 315M USD
- Date 2023-03: Value 332M USD
- Date 2023-04: Value 395M USD
- Date 2023-05: Value 356M USD
- Date 2023-06: Value 331M USD
- Date 2023-07: Value 301M USD
- Date 2023-08: Value 342M USD
- Date 2023-09: Value 416M USD
- Date 2023-10: Value 296M USD
- Date 2023-11: Value 388M USD
- Date 2023-12: Value 407M USD
- Date 2024-01: Value 470M USD
- Date 2024-02: Value 348M USD
- Date 2024-03: Value 520M USD
- Date 2024-04: Value 453M USD
- Date 2024-05: Value 391M USD
- Date 2024-06: Value 531M USD
- Date 2024-07: Value 453M USD
- Date 2024-08: Value 445M USD
- Date 2024-09: Value 391M USD
- Date 2024-10: Value 432M USD
- Date 2024-11: Value 466M USD
- Date 2024-12: Value 469M USD
- Date 2025-01: Value 528M USD
- Date 2025-02: Value 313M USD
- Date 2025-03: Value 468M USD
- Date 2025-04: Value 490M USD
- Date 2025-05: Value 739M USD
- Date 2025-06: Value 407M USD
- Date 2025-07: Value 610M USD
- Date 2025-08: Value 906M USD
- Date 2025-09: Value 747M USD
- Date 2025-10: Value 746M USD
- Date 2025-11: Value 570M USD
- Date 2025-12: Value 562M USD
- Date 2026-01: Value 577M USD
- Date 2026-02: Value 718M USD
- Date 2026-03: Value 647M USD
- Date 2026-04: Value 512M USD
- Date 2026-05: Value 526M USD
- Date 2026-06: Value 725M USD
- Date 2026-07: Value 879M USD
Top destinations
- Germany26B
- France12.7B
- United States12.4B
- Italy10.3B
- Denmark8.8B
- Sweden8.5B
- Australia7.2B
- United Kingdom6.4B
- Japan4.4B
- Switzerland4B
Top destinations
- Germany: 26,009,000,000 USD
- France: 12,712,000,000 USD
- United States: 12,378,000,000 USD
- Italy: 10,299,000,000 USD
- Denmark: 8,752,000,000 USD
- Sweden: 8,481,000,000 USD
- Australia: 7,216,000,000 USD
- United Kingdom: 6,409,000,000 USD
- Japan: 4,441,000,000 USD
- Switzerland: 4,043,000,000 USD
Key findings
Largest import market
26.01B USD
Germany · last 8 years
Fastest demand growth
58,020.6
Montenegro · last 8 years
Highest unit price
$257,640 /kg
United Arab Emirates · +6,231.89% vs avg
Turn this market into qualified conversations.
Your agent contacts, compares, and screens the suppliers that fit.
Insights
Product insights to guide your sourcing.
Product Trends
Sustained-release oral doses and pre-filled injectables see steady B2B growth. Advanced drug delivery systems, such as oral disintegrating films, represent a key emerging category with high procurement potential.
Industrial Cluster Analysis
The Yangtze River Delta specializes in advanced formulation CDMO services with strict cGMP compliance. North China focuses on high-volume production of classic generic preparations integrated with active API manufacturing.
Quality Expectations
Preparations must maintain stable active ingredient dissolution and purity throughout their shelf life under designated climatic zones. Buyers require strict compliance with USP/EP standards and proof of bioequivalence.
What You Need to Know
Request recent Certificates of Analysis, stability testing data, and bioequivalence reports. For contract manufacturing, arrange a third-party cGMP plant audit and verify active ingredient purity before placing orders.
Generic formulation MOQs typically range from 100,000 to 500,000 units per batch to optimize automated runs. Production takes 60 to 90 days; allow additional time for regulatory clearances and shipping transit.
Budget for local regulatory registration, bioequivalence testing, import duties, temperature-controlled shipping for sensitive products, customized packaging printing, and pre-shipment third-party inspections.
